Dimensional Fund Advisors LP Has $140.84 Million Stake in Roivant Sciences Ltd. $ROIV

Dimensional Fund Advisors LP raised its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 18.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,308,710 shares of the company’s stock after purchasing an additional 1,423,074 shares during the period. Dimensional Fund Advisors LP owned approximately 1.36% of Roivant Sciences worth $140,839,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Perceptive Advisors LLC acquired a new stake in shares of Roivant Sciences in the second quarter valued at approximately $37,546,000. Orbimed Advisors LLC acquired a new stake in Roivant Sciences during the second quarter worth approximately $31,324,000. Rubric Capital Management LP increased its stake in Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after acquiring an additional 2,603,260 shares during the period. Squarepoint Ops LLC raised its holdings in Roivant Sciences by 2,580.0% in the 2nd quarter. Squarepoint Ops LLC now owns 2,211,675 shares of the company’s stock valued at $24,926,000 after acquiring an additional 2,129,150 shares in the last quarter. Finally, Candriam S.C.A. raised its holdings in Roivant Sciences by 5,399.5% in the 2nd quarter. Candriam S.C.A. now owns 1,503,994 shares of the company’s stock valued at $16,951,000 after acquiring an additional 1,476,646 shares in the last quarter. 64.76% of the stock is owned by institutional investors.

Insider Activity at Roivant Sciences

In other news, insider Frank Torti sold 587,390 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $27.51, for a total value of $16,159,098.90. Following the completion of the transaction, the insider directly owned 13,736,547 shares in the company, valued at approximately $377,892,407.97. This represents a 4.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $26.49, for a total value of $5,298,000.00. Following the sale, the chief executive officer owned 1,654,597 shares in the company, valued at $43,830,274.53. This represents a 10.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 13,118,014 shares of company stock valued at $311,557,023. 10.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. HC Wainwright upped their price objective on shares of Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Weiss Ratings downgraded shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, February 9th. The Goldman Sachs Group raised their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Citigroup boosted their target price on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $28.81.

Roivant Sciences Stock Up 0.6%

Shares of ROIV stock opened at $29.70 on Wednesday. The business has a fifty day simple moving average of $24.88 and a 200 day simple moving average of $20.40. The company has a market cap of $21.26 billion, a P/E ratio of -25.38 and a beta of 1.17. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $30.30.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.